1. What Is Reasonable and Necessary for Alzheimer Patients from Randomized Clinical Trials to Clinical Practice?

   • Lefkos T. Middleton
   • J. Touchon
   • B. Vellas

   Editorial 13 June 2023 Pages: 331 - 332

2. «Compounded Interest» in Alzheimer’s Disease: Do New Amyloid-Targeting Treatments Justify Their Use

   • Cristina Sampaio

   Viewpoint 13 June 2023 Pages: 333 - 335

   

3. Balancing the Conflicting Goals for Treatment of Alzheimer’s Disease with Monoclonal Antibodies

   • David R. Scrase
   • N. Budhwar

   Viewpoint 13 June 2023 Pages: 336 - 338

4. Clinicians’ Perspectives on How Disease Modifying Drugs for Alzheimer’s Disease Impact Specialty Care

   • Serge Gauthier
   • Z. Ismail
   • P. Rosa-Neto

   Viewpoint 13 June 2023 Pages: 339 - 341

5. When It Comes to Lecanemab (and Donanemab), How Might We Think about ‘Reasonable and Necessary’?

   • Lon S. Schneider

   Viewpoint 13 June 2023 Pages: 342 - 343

6. What Is Reasonable and Necessary for People Living with AD after the FDA Approves a Treatment?

   • Rachelle S. Doody
   • S. Skerjanec

   Point of View 13 June 2023 Pages: 344 - 345

7. Defining FDA Approved Treatments as Reasonable and Necessary: Perspectives of Individuals Living with Alzheimer’s Disease and Care Partners

   • M. C. Carrillo
   • M. Moreno

   Viewpoint 13 June 2023 Pages: 346 - 348

8. Amyloid-targeting New Therapies for Alzheimer’s Disease: A Health Economics Perspective

   • L. Jönsson
   • Anders Wimo

   Viewpoint 13 June 2023 Pages: 349 - 352

   

9. Clinical Implementation of Lecanemab: Challenges, Questions and Solutions

   • Takeshi Iwatsubo

   Editorial 06 April 2023 Pages: 353 - 355

10. Appropriate Use Recommendations for Lecanemab

    • Michael S. Rafii

    Editorial 31 March 2023 Pages: 356 - 356

11. Lecanemab: Appropriate Use Recommendations — A Commentary from a European Perspective

    • Lutz Frölich
    • F. Jessen

    Editorial 08 April 2023 Pages: 357 - 358

12. Implications of Emerging Uses of Genetic Testing for Alzheimer’s Disease

    • Drew Blasco
    • J. S. Roberts

    Editorial 17 April 2023 Pages: 359 - 361

13. Lecanemab: Appropriate Use Recommendations

    • J. Cummings
    • L. Apostolova
    • For the Alzheimer’s Disease and Related Disorders Therapeutics Work Group

    Review Open access 27 March 2023 Pages: 362 - 377

    

14. Clinical Efficacy in Individual Patients Treated with Lecanemab

    • Serge Gauthier
    • J. Therriault
    • P. Rosa-Neto

    Commentary 17 May 2023 Pages: 378 - 379

    

15. Expanding the ATN Framework to Further Personalize Therapies

    • S. Gauthier
    • Pedro Rosa-Neto

    Editorial 03 May 2023 Pages: 380 - 380

16. Adding the Topographical Information from Tau-PET to the A/T/(N) Framework: Steps Towards Staging AD in Vivo

    • J. Therriault
    • S. Gauthier
    • Pedro Rosa-Neto

    Special Article 03 May 2023 Pages: 381 - 386

    

17. White Matter Hyperintensity as a Vascular Contribution to the AT(N) Framework

    • Kok Pin Ng
    • J. Y. Shen
    • S. Gauthier

    Review 03 May 2023 Pages: 387 - 400

    

18. Neuroinflammation Biomarkers in the AT(N) Framework Across the Alzheimer’s Disease Continuum

    • A. Bieger
    • A. Rocha
    • Eduardo R. Zimmer

    Review 03 May 2023 Pages: 401 - 417

    

19. Can We Use Blood Biomarkers as Entry Criteria and for Monitoring Drug Treatment Effects in Clinical Trials? A Report from the EU/US CTAD Task Force

    • D. Angioni
    • O. Hansson
    • Jin Zhou

    CTAD Task Force Paper 13 June 2023 Pages: 418 - 425

20. Diagnostic Biomarkers of Amyloid and Tau Pathology in Alzheimer’s Disease: An Overview of Tests for Clinical Practice in the United States and Europe

    • Leonardo Iaccarino
    • S. C. Burnham
    • S. Epelbaum

    Review Open access 06 April 2023 Pages: 426 - 442

    

21. Adult Renal Dysfunction and Risk of Dementia or Cognitive Decline: Brain-Kidney Axis Hypothesis Based on a Systematic Review and Meta-Analysis

    • H.-C. Chi
    • Y. Liu
    • Wei Xu

    Review 05 April 2023 Pages: 443 - 452

    

22. Outreach, Screening, and Randomization of APOE ε4 Carriers into an Alzheimer’s Prevention Trial: A global Perspective from the API Generation Program

    • T. Walsh
    • L. Duff
    • Jessica Langbaum

    Original Research Open access 14 March 2023 Pages: 453 - 463

    

23. Combined Evidence for a Long-Term, Clinical Slowing Effect of Multinutrient Intervention in Prodromal Alzheimer’s Disease: Post-Hoc Analysis of 3-Year Data from the LipiDiDiet Trial

    • Suzanne B. Hendrix
    • H. Soininen
    • LipiDiDiet clinical study group

    Original Research Open access 26 March 2023 Pages: 464 - 470

    

24. Cohort Effects in Alzheimer’s Disease Trials: An Empirical Assessment Utilizing Data from the Alzheimer’s Disease Cooperative Study

    • Adam I. Birnbaum
    • J. D. Grill
    • D. L. Gillen

    Original Research Open access 12 April 2023 Pages: 471 - 477

    

25. Validation of the CogDrisk Instrument as Predictive of Dementia in Four General Community-Dwelling Populations

    • S. Kootar
    • M. H. Huque
    • Kaarin J. Anstey

    Original Research Open access 11 April 2023 Pages: 478 - 487

26. Usefulness of Community Pharmacy for Early Detection of Cognitive Impairment in Older People Using the IQ-CODE Questionnaire

    • L. F. Agüera Ortiz
    • G. García-Ribas
    • Grupo de estudio NEURAXCARE

    Original Research 06 April 2023 Pages: 488 - 496

    

27. Physical Activity Is Associated with Slower Cognitive Decline in Older Adults with Type 2 Diabetes

    • Yaacov Rabinowitz
    • R. Ravona-Springer
    • M. Schnaider-Beeri

    Original Research 14 March 2023 Pages: 497 - 502

    

28. Pushing through the Barriers: Peer Advice to Increase Physical Activity and Reduce Dementia Risk from Participants in a Massive Open Online Alzheimer’s Focused Course

    • M. R. Abela
    • H. Maxwell
    • K. Lawler

    Original Research Open access 11 April 2023 Pages: 503 - 512

    

29. Association of Circulating Caprylic Acid with Risk of Mild Cognitive Impairment and Alzheimer’s Disease in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) Cohort

    • L. Fan
    • X. Zhu
    • Qi Dai

    Original Research 05 April 2023 Pages: 513 - 522

    

30. Association between Neuropsychological Performance and CSF Profile in Subjective Cognitive Decline: Towards the Diagnosis of Preclinical AD

    • E. Chipi
    • G. Bellomo
    • Lucilla Parnetti

    Original Research Open access 01 April 2023 Pages: 523 - 529

    

31. Reproductive Markers in Alzheimer’s Disease Progression: The Framingham Heart Study

    • Huitong Ding
    • Y. Li
    • Chunyu Liu

    Original Research 22 March 2023 Pages: 530 - 535

    

32. A Genetic Validation of the Neurodegeneration Biomarkers Tau-A and Tau-C - A Mendelian Randomization Study

    • T. M. Axelsen
    • C. Bager
    • M. H. E. Tang

    Original Research 05 April 2023 Pages: 536 - 542

    

33. Association between Longitudinal Cerebrospinal Fluid Alzheimer’s Biomarkers and the Lifestyle for Brain Health (LIBRA) Index: Findings from the European Prevention of Alzheimer’s Dementia Cohort Study (EPAD LCS)

    • Tyler S. Saunders
    • M. Protsiv
    • G. Muniz-Terrera

    Original Research 28 March 2023 Pages: 543 - 550

    

34. Understanding Online Registry Facilitators and Barriers Experienced by Black Brain Health Registry Participants: The Community Engaged Digital Alzheimer’s Research (CEDAR) Study

    • Miriam T. Ashford
    • D. Zhu
    • R. L. Nosheny

    Original Research Open access 14 March 2023 Pages: 551 - 561

    

35. Subjective Cognitive Complaints: Comparing the Relation between Self-Reported Versus Informant-Reported Subjective Cognitive Complaints and Cognitive Performances in Cognitively Unimpaired, Mild Cognitive Impairment and Populations with Dementia

    • S.-W. Peng
    • C.-Y. Wang
    • Pei-Ning Wang

    Original Research 19 April 2023 Pages: 562 - 570

    

36. Chinese Preclinical Alzheimer’s Disease Study (C-PAS): Design and Challenge from PET Acceptance

    • L. Cui
    • L. Huang
    • Qihao Guo

    Original Research 03 May 2023 Pages: 571 - 580

    

37. Neuroprotective Effects of IVIG against Alzheimer’s Disease via Regulation of Antigen Processing and Presentation by MHC Class I Molecules in 3xTg-AD Mice

    • Z. Fei
    • B. Pan
    • Haijun Cao

    Original Research Open access 03 May 2023 Pages: 581 - 594

    

38. ‘Time Saved’ As a Demonstration of Clinical Meaningfulness and Illustrated Using the Donanemab TRAILBLAZER-ALZ Study Findings

    • S. P. Dickson
    • Alette M. Wessels
    • S. Hendrix

    Brief Report Open access 03 May 2023 Pages: 595 - 599

    

39. Ten Years after the National Alzheimer’s Plan: Dementia Remains a Hidden Syndrome in France

    • J.-F. Dartigues
    • J. A. Avila-Funes
    • Karine Pérès

    Brief Report 09 March 2023 Pages: 600 - 606

    

40. Associations between Participant Characteristics and Participant Feedback about an Unsupervised Online Cognitive Assessment in a Research Registry

    • Miriam T. Ashford
    • J. Eichenbaum
    • R. L. Nosheny

    Brief Communication Open access 19 April 2023 Pages: 607 - 614